Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus placebo for severe indolent or smouldering systemic mastocytosis
NL-OMON55076Phase 3Completed
- Sponsor
- AB Science
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic mastocytosis (SM) and indolent systemic mastocytosis (ISM) comparing Masitinib with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2022; status: completed.
02
Drugs
masitinib
03
Conditions
systemic mastocytosis (SM)indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on NL-OMON55076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55076.